Get the Stockscreener App
8.49
2.78%
0.23
After Hours:
8.64
0.15
+1.77%
Korro Bio Inc stock is traded at $8.49, with a volume of 281.42K.
It is up +2.78% in the last 24 hours and up +20.94% over the past month.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
See More
Previous Close:
$8.26
Open:
$8.31
24h Volume:
281.42K
Relative Volume:
0.62
Market Cap:
$79.95M
Revenue:
-
Net Income/Loss:
$-81.17M
P/E Ratio:
-0.8377
EPS:
-10.1344
Net Cash Flow:
$-82.84M
1W Performance:
+5.99%
1M Performance:
+20.94%
6M Performance:
-32.51%
1Y Performance:
-77.87%
1-Day Range:
$8.1443
$8.635
1-Week Range:
$7.82
$8.635
52-Week Range:
$5.2044
$55.89
Korro Bio Inc Stock (KRRO) Company Profile
Name
Korro Bio Inc
Sector
Industry
Phone
617-468-1999
Address
60 FIRST STREET, CAMBRIDGE
Compare KRRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
8.49 | 77.79M | 0 | -81.17M | -82.84M | -10.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-13-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-13-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-13-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-13-25 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Nov-13-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-16-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Raymond James | Strong Buy |
| Aug-14-24 | Initiated | William Blair | Outperform |
| Mar-28-24 | Reiterated | H.C. Wainwright | Buy |
| Feb-27-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-04-23 | Initiated | H.C. Wainwright | Buy |
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-10-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-13-23 | Downgrade | Cowen | Outperform → Market Perform |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jan-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-28-19 | Initiated | Cowen | Outperform |
| Oct-28-19 | Initiated | Goldman | Buy |
| Oct-28-19 | Initiated | JP Morgan | Overweight |
View All
Korro Bio Inc Stock (KRRO) Latest News
Will Korro Bio Inc. stock keep outperforming rivals2026 world cup usa national team third place match key players low block defense winner prediction expert opinion - ulpravda.ru
Aug Analyst Calls: Will Korro Bio Inc stock see insider buyingWeekly Market Outlook & Entry and Exit Point Strategies - moha.gov.vn
Korro Bio enhances executive compensation and retention incentives - MSN
Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Rating of “Hold” from Analysts - Defense World
Why analysts remain bullish on Korro Bio Inc. stockIPO Watch & Free Low Drawdown Momentum Trade Ideas - Улправда
Can Korro Bio Inc. stock surprise with earnings upsideDividend Hike & Accurate Trade Setup Notifications - Улправда
Will Korro Bio Inc. stock see insider buyingTrade Exit Summary & Real-Time Volume Analysis - bolumsonucanavari.com
Korro Bio (KRRO) price target decreased by 30.77% to 45.90 - MSN
Published on: 2025-12-20 09:40:01 - Улправда
Loss Report: Why Korro Bio Inc. stock remains resilient2025 Major Catalysts & Free Real-Time Volume Trigger Notifications - Улправда
How institutional buying supports Korro Bio Inc. stock2025 Trading Volume Trends & Trade Opportunity Analysis Reports - Улправда
Why Korro Bio Inc. stock remains resilientJuly 2025 WrapUp & Daily Profit Focused Screening - Улправда
How Korro Bio Inc. stock performs after earningsMarket Performance Recap & Long-Term Safe Investment Plans - Улправда
How Korro Bio Inc. stock reacts to oil prices2025 Trading Volume Trends & Stock Portfolio Risk Management - Улправда
Aug Decliners: Will Korro Bio Inc. stock benefit from sector rotation2025 Stock Rankings & Momentum Based Trading Signals - DonanımHaber
BostInnoMass. showing at CES | Korro's $116M Series B - The Business Journals
Korro Bio amends employment agreement with Jeffrey Cerio, increases compensation - Investing.com Canada
Korro Bio Enhances Executive Compensation and Retention Incentives - TipRanks
Korro Bio (KRRO) boosts Jeffrey Cerio salary, severance and RSU grant - Stock Titan
Can Korro Bio Inc. stock resist market sell offsJuly 2025 Retail & AI Enhanced Execution Alerts - Улправда
Will Korro Bio Inc. stock continue dividend increasesMarket Risk Analysis & Fast Moving Stock Trade Plans - Улправда
Why Korro Bio Inc. stock could be next big winner2025 Top Gainers & Safe Entry Trade Signal Reports - Улправда
Korro Bio’s KRRO-110 Study: A Potential Game-Changer in Genetic Therapy - MSN
Korro Bio (NASDAQ:KRRO) Lowered to Sell Rating by Wall Street Zen - Defense World
Korro Bio downgraded to Hold from Buy at Clear Street - MSN
Stocks of Korro Bio Inc (KRRO) are poised to climb above their peers - setenews.com
Is Korro Bio Inc a good long term investmentCapital Gains Strategies & Small Entry Cost Stocks - earlytimes.in
Will Magenta Lifecare Limited Stock Continue to Outperform in YEARInsider Trading Activity & Market Volatility Strategies - earlytimes.in
Three new option listings and fifteen option delistings on October 21st - MSN
Korro Bio, Inc. Experiences Revision in Stock Evaluation Amid Mixed Financial Performance - Markets Mojo
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of “Hold” from Analysts - Defense World
Its Stock Has Paid Off Big Time For Korro Bio Inc - Setenews
Korro Bio’s RNA Editing Ambitions Take A Hit After Trial Blowup - Finimize
Would You Still Hold Korro Bio Stock If It Fell Another 30%? - Trefis
Korro Bio downgraded to Perform from Outperform at Oppenheimer - MSN
What high frequency data says about Korro Bio Inc.Portfolio Profit Report & Daily Oversold Bounce Ideas - newser.com
Will Korro Bio Inc. stock benefit from automationBear Alert & Technical Analysis for Trade Confirmation - newser.com
What indicators show strength in Korro Bio Inc.Portfolio Value Report & Consistent Income Trade Recommendations - newser.com
Will Korro Bio Inc. stock deliver strong dividend growthPortfolio Performance Summary & Growth Focused Investment Plans - newser.com
What makes Korro Bio Inc. stock attractive to growth fundsJuly 2025 News Drivers & Weekly High Return Stock Forecasts - newser.com
What is the fair value of Korro Bio Inc. stock nowJuly 2025 Earnings & Reliable Volume Spike Alerts - newser.com
Korro Bio, Inc.Common Stock (NQ: KRRO - FinancialContent
FY2025 EPS Estimates for Korro Bio Raised by HC Wainwright - Defense World
Korro Bio (KRRO) Price Target Decreased by 30.76% to 66.30 - MSN
Korro Bio stock fell after missing expectations in early stage KRRO-110 trial - MSN
Korro Bio Inc Stock (KRRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):